Novo Nordisk launched an oral formulation of its obesity drug Wegovy in the US, setting insured patient co-pay as low as $25 per month and a $149 cash price. The company disclosed the pricing ahead of prescriptions becoming available, signaling a rapid push to capture the oral GLP‑1 market. The move shifts a high-cost injectable franchise to an oral option and tightens competition among GLP‑1 makers and payers. Payer and provider adoption will determine uptake; lower-insured pricing may accelerate clinic prescribing but also raises questions about coverage rules and prior authorization. GLP‑1 receptor agonists are incretin-based therapies that modulate appetite and glucose control; an oral formulation changes delivery and distribution dynamics.